Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF …

MN Kosiborod, J Deanfield, R Pratley, BA Borlaug… - The Lancet, 2024 - thelancet.com
Background Heart failure with mildly reduced or preserved ejection fraction (hereafter
referred to as HFpEF) is the most common type of heart failure and is associated with a high …

A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a …

DW Kitzman, GD Lewis, A Pandey… - European Journal of …, 2024 - Wiley Online Library
Aims Compared with those without obesity, patients with obesity‐related heart failure with
preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes …

Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial

S Takeuchi, T Kohno, A Goda, Y Shiraishi… - International Journal of …, 2023 - Elsevier
Background Despite the benefits of the sodium-glucose cotransporter 2 inhibitor (SGLT2i)
empagliflozin, its suitability for patients with heart failure (HF) in the real-world setting …

[HTML][HTML] Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction

T Kondo, R Campbell, PS Jhund, IS Anand… - JACC: Heart Failure, 2024 - Elsevier
Background Although some patients with heart failure (HF) with mildly reduced/preserved
ejection fraction have low natriuretic peptide levels, there are no large-scale systematic …

Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction

AE Peters, RM Clare, K Chiswell, J Harrington… - ESC Heart …, 2024 - Wiley Online Library
Aims Clinical trials in heart failure with mildly reduced or preserved ejection fraction
(HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to …

[PDF][PDF] Inclusion criteria for heart failure with preserved ejection fraction clinical trials: making the case for precision diagnosis and greater inclusivity

RB Patel, SJ Shah - Journal of cardiac failure, 2022 - Elsevier
Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous clinical
syndrome that results in resting or exertional left atrial pressure elevation with concomitant …

[HTML][HTML] 射血分数保留性心力衰竭研究进展

赵小利, 刘青华, 刘新宏 - Advances in Clinical Medicine, 2022 - hanspub.org
射血分数保留性心力衰竭(HFPEF) 是一种复杂且具有异质性的疾病, 近年来随着人们保健意识的
增强, HFPEF 的发病率也呈持续升高的趋势, 目前占所有心力衰竭的一半, 其发病机制还未完全 …

[HTML][HTML] Is the Weight Over? An Improved HFpEF Risk Score

MN Belkin, R Sachar, P Goyal - JACC: Advances, 2024 - jacc.org
Given recent advances in therapeutic options for heart failure with preserved ejection
fraction (HFpEF), noninvasive screening and diagnostic tools are critical to accurately …

[HTML][HTML] Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction

CS Morgen, CL Haase, TK Oral, V Schnecke… - Mayo Clinic …, 2023 - Elsevier
Objective To compare clinical features of patients with obesity-related heart failure (HF) with
preserved ejection fraction (HFpEF) with those of patients with similar body mass index …